Scholarlink

Objective and design <p>This prospective multicenter cohort study was conducted to identify and compare clinical factors associated with the effectiveness of commonly used biologics in Chinese patients with moderate-to-severe psoriasis.</p> Subjects <p>Patients from the SPEECH registry initiating treatment with ixekizumab, secukinumab, guselkumab, or ustekinumab were included.</p> Treatment <p>Guideline-recommended dosing; 3-month follow-up.</p> Methods <p>The primary endpoint was PASI90 response at 3&#xa0;months. Multivariable logistic regression estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for clinical predictors of treatment response.</p> Results <p>A total of 717 patients were included in the analysis. In guselkumab-treated patients, obesity (aOR 0.22, 95% CI 0.06–0.78) and prior biologic exposure (aOR 0.22, 95% CI 0.06–0.75) were independently associated with reduced PASI90 response. Psoriatic arthritis predicted poorer response to ustekinumab (aOR 0.16, 95% CI 0.03–0.78). For secukinumab, male sex reduced the likelihood of PASI90 (aOR 0.47, 95% CI 0.23–0.96), whereas family history of psoriasis improved outcomes (aOR 2.20, 95% CI 1.10–4.42). In ixekizumab-treated patients, obesity (aOR 0.38, 95% CI 0.18–0.80) was a negative predictor, while family history (aOR 2.79, 95% CI 1.22–6.38) enhanced treatment response.</p> Conclusions <p>Predictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China

  • 期刊论文

  • 发表日期：

    2026年1月27日

查看全文
  • Min Dai,
  • Yuxiong Jiang,
  • Yuanyuan Wang,
  • Dawei Huang,
  • Yu Wang,
  • Yifan Hu,
  • Yunlu Gao,
  • Qian Yu,
  • Yuling Shi

摘要

Objective and design

This prospective multicenter cohort study was conducted to identify and compare clinical factors associated with the effectiveness of commonly used biologics in Chinese patients with moderate-to-severe psoriasis.

Subjects

Patients from the SPEECH registry initiating treatment with ixekizumab, secukinumab, guselkumab, or ustekinumab were included.

Treatment

Guideline-recommended dosing; 3-month follow-up.

Methods

The primary endpoint was PASI90 response at 3 months. Multivariable logistic regression estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for clinical predictors of treatment response.

Results

A total of 717 patients were included in the analysis. In guselkumab-treated patients, obesity (aOR 0.22, 95% CI 0.06–0.78) and prior biologic exposure (aOR 0.22, 95% CI 0.06–0.75) were independently associated with reduced PASI90 response. Psoriatic arthritis predicted poorer response to ustekinumab (aOR 0.16, 95% CI 0.03–0.78). For secukinumab, male sex reduced the likelihood of PASI90 (aOR 0.47, 95% CI 0.23–0.96), whereas family history of psoriasis improved outcomes (aOR 2.20, 95% CI 1.10–4.42). In ixekizumab-treated patients, obesity (aOR 0.38, 95% CI 0.18–0.80) was a negative predictor, while family history (aOR 2.79, 95% CI 1.22–6.38) enhanced treatment response.

Conclusions

Predictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics.